Hair-Loss Telehealth Pricing Index

Direct answer

The RightFit Hair-Loss Telehealth Pricing Index now includes major men’s and women’s programs from Ro, Hims, Hers, Keeps, Happy Head, Mochi, Shed, Nurx, Musely, Alloy, Winona, and other tracked providers. The dataset spans standalone finasteride and minoxidil, oral and topical routes, postmenopausal formulas, customized compounded combinations, spironolactone, lash-growth treatments, and different subscription terms. Each price remains tied to its formulation and source.

Standalone oral minoxidil

Finasteride + minoxidil combinations

Men’s multi-ingredient products

Women’s multi-ingredient products

The current index contains both published and review pricing states

Mochi currently provides published prices for standalone oral minoxidil and compounded finasteride/minoxidil combination products. Several Shed multi-ingredient hair products are verified as current offerings but their price rows remain in review because the same provider page displays conflicting monthly or quarterly billing figures.

The index treats those states differently. A published price is eligible for current market summaries. A review price can support editorial discussion of the product and the pricing conflict but should not be included as a verified public market price until the source is reconciled.

Oral minoxidil requires distinct regulatory context

Current official oral minoxidil tablet labeling describes minoxidil as an antihypertensive drug. RightFit therefore does not present a telehealth oral minoxidil hair program as an FDA-approved oral hair-loss product. The provider can still be listed and priced as a current telehealth offering, but the labeled product context remains separate.

Finasteride has an approved hair-loss product, but combinations remain separate

Finasteride 1 mg has an approved indication for male pattern hair loss in men. That fact does not make a compounded finasteride/minoxidil capsule or serum FDA-approved. The index uses the official finasteride label as the single-ingredient approved reference while preserving compounded status for the tracked combination products.

Why the index does not average by ingredient alone

A minoxidil-containing product can be standalone or combined with finasteride, spironolactone, biotin, tretinoin, vitamin E, fluocinolone, or other ingredients. Averaging every product that contains minoxidil would produce a number that mixes different formulas, routes, supply periods, and billing structures. RightFit therefore calculates treatment-level views from the structured formulation records rather than from keyword matches.

Route should remain visible in every price comparison

Oral tablets and capsules are different commercial products from topical serums. Even when the ingredient list overlaps, route can affect formulation, supply packaging, provider instructions, and pricing. The index therefore does not collapse oral and topical versions into one observation.

Membership structure can change the practical recurring cost

Mochi’s current hair medication prices require a separate membership. Shed’s current multi-ingredient products use a different subscription and supply structure. RightFit stores medication pricing, membership, and included services separately so a low medication price does not automatically appear to be the full recurring cost.

Quarterly billing can look monthly in marketing

Several Shed hair pages display monthly-looking amounts while the billing section describes a 90-day or quarterly charge. That makes it essential to preserve the actual supply and billing term. When the provider page contains two monthly figures that do not reconcile, RightFit keeps the price in review instead of selecting the more attractive number.

Compounded products should not inherit approval from individual ingredients

FDA states that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality. A compounded multi-ingredient hair product can contain an ingredient with an approved standalone product without becoming an FDA-approved combination. RightFit keeps that distinction attached to the preparation type.

What the index counts

• Verified current provider-treatment programs.
• Exact formulation and route.
• Published price observations that have cleared source review.
• Review pricing kept outside verified market summaries.
• Supply duration and billing period.
• Required membership or recurring care fee.
• Included clinician access and shipping when verified.
• Program-specific state availability when verified.
• Provider-primary source and verification date.
• Regulator-primary context for product labeling and compounding.

What the index does not treat as interchangeable

• Standalone oral minoxidil and topical minoxidil-containing combinations.
• Standalone finasteride 1 mg and compounded finasteride/minoxidil combinations.
• Oral and topical combination products.
• Two-ingredient and multi-ingredient formulations.
• Published and review pricing.
• Medication-only prices and prices paired with a separate membership.
• A monthly equivalent and true month-to-month billing.

Why market medians need careful selection

A useful median should be built from comparable verified observations. Including review prices, multi-month effective rates, oral and topical products, or medication-only and bundled program prices in one undifferentiated statistic can make the result look precise while obscuring the actual market. RightFit therefore keeps the underlying dimensions available for segmented analysis.

Product definitions can be verified before price

A current provider page can establish the route and ingredients even when its billing language is contradictory. RightFit can preserve those product facts while withholding the price. This separation allows the index to stay useful without rewarding an unclear sales page with false precision.

Why source freshness is especially important for compounded hair products

Providers can revise ingredient combinations, strengths, supply periods, or billing terms while keeping a familiar product name. RightFit therefore favors the current dedicated product page and treats a material formula change as more than a simple price update.

How to use the hair pricing index

• Start with the exact formulation, not only the ingredient name.
• Check oral versus topical route.
• Identify every active ingredient in a combination product.
• Separate standalone from compounded combination programs.
• Use only published verified prices for price comparisons.
• Add any required membership or program fee.
• Check the actual supply and billing term.
• Treat conflicting first-party prices as unresolved.
• Review the current source date before relying on the displayed offer.

What the index cannot decide

The pricing index cannot determine whether a hair-loss medication is appropriate for an individual, whether oral or topical treatment is preferable, or whether a multi-ingredient combination produces better results. Those are clinical questions separate from the public program and pricing dataset.

Bottom line

The telehealth hair-loss market is more complex than a list of finasteride and minoxidil prices. RightFit now captures major programs from Ro, Hims, Hers, Keeps, Happy Head, Mochi, Nurx, Musely, Alloy, Winona, Shed, and other providers, while keeping standard versus promotional prices, oral versus topical routes, shipment fees, memberships, population-specific formulas, and unresolved source conflicts separate.

Why review prices stay outside the verified index statistics

A provider page can contain enough information to verify that a product exists while still failing the price-verification standard. Shed’s current hair pages illustrate this problem: the formulation and quarterly supply are identifiable, but several pages display conflicting monthly figures. Including those rows in a median or minimum would make the index look more complete while weakening its accuracy. RightFit therefore keeps review observations visible internally but excludes them from verified public price summaries until the source conflict is resolved.

Why the index should separate product count from price count

The number of verified hair programs can be larger than the number of published price observations because a product can be verified without a usable current price. RightFit treats those as different metrics. Program count answers how much of the market is mapped; published-price count answers how much of that market currently has a price that meets the source standard.

Memberships can distort an ingredient-level comparison

Mochi’s medication prices require a separate membership, while other providers can include clinical access inside the treatment amount. A raw comparison of medication numbers would therefore understate the recurring structure for one provider and potentially overstate it for another. RightFit keeps membership and medication separate so both the source price and the broader commercial obligation remain visible.

The index is designed to support future change tracking

Once a provider’s current baseline is verified, later changes can be classified more precisely: a price change, membership change, supply-term change, ingredient change, route change, or source conflict. That makes the index more useful than a static list of prices because it can explain why a provider’s offer changed instead of only showing that a number is different.

The same method also protects future expansion. If RightFit adds another hair provider, the new product can enter the index at the correct formulation and price-status level without forcing current oral, topical, standalone, combination, published, and review records into one simplified category.

This also means a new verified Shed price can be published later without rewriting the product history: the review observation can be resolved against the current first-party billing terms while the formulation record stays intact.